Trial · NCT01353222

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

NCT01353222, Phase 2, Terminated, Dendreon; results first posted 2017-05-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma. Trials, record NCT01353222. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01353222

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
NCT number: NCT01353222
Status: Terminated
Phases: Phase 2
Enrollment: 142 participants, actual
Lead sponsor: Dendreon
Conditions: Urothelial Carcinoma
Interventions: DN24-02, Standard of Care
First posted: 2011-05-13
Last updated: 2017-05-25
Results first posted: 2017-05-25

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival	Subjects will be followed from baseline through the remainder of their lives or until study completion (approximately 60 months)	Overall survival is defined as the time from randomization to death due to any cause. \*This study was terminated early due to administrative reasons.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival	Subjects will be followed from baseline through the remainder of their lives or until study completion (approximately 60 months)	Intent to Treat (ITT) population.~\*This study was terminated early due to administrative reasons.	Months	MEDIAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Overall Survival	DN24-02		17.2	Full Range 0.1 to 42.4	Months
Overall Survival	Standard of Care		18	Full Range 0.3 to 40.2	Months

Source ClinicalTrials.gov

Participant flow10

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	DN24-02	70
Overall Study	STARTED	Standard of Care	72
Overall Study	DN24-02 Arm ≥1 Leukapheresis	DN24-02	67
Overall Study	DN24-02 Arm ≥1 Leukapheresis	Standard of Care	0
Overall Study	Standard Care Arm ≥1 Post-baseline Visit	DN24-02	0
Overall Study	Standard Care Arm ≥1 Post-baseline Visit	Standard of Care	72
Overall Study	COMPLETED	DN24-02	0
Overall Study	COMPLETED	Standard of Care	0
Overall Study	NOT COMPLETED	DN24-02	70
Overall Study	NOT COMPLETED	Standard of Care	72

Source ClinicalTrials.gov

Adverse events194

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	ANAEMIA	Blood and lymphatic system disorders	DN24-02	8	67	8
other	ANAEMIA	Blood and lymphatic system disorders	Standard of Care	5	72	6
other	CONSTIPATION	Gastrointestinal disorders	DN24-02	14	67	15
other	CONSTIPATION	Gastrointestinal disorders	Standard of Care	10	72	10
other	NAUSEA	Gastrointestinal disorders	DN24-02	18	67	27
other	NAUSEA	Gastrointestinal disorders	Standard of Care	6	72	6
other	ABDOMINAL PAIN	Gastrointestinal disorders	DN24-02	9	67	9
other	ABDOMINAL PAIN	Gastrointestinal disorders	Standard of Care	9	72	9
other	VOMITING	Gastrointestinal disorders	DN24-02	10	67	17
other	VOMITING	Gastrointestinal disorders	Standard of Care	7	72	7

1 to 10 of 194Source ClinicalTrials.gov

See all 194 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	DN24-02	30	67
Total, all-cause mortality	Standard of Care	30	72
Total, other adverse events	DN24-02	64	67
Total, other adverse events	Standard of Care	52	72
Total, serious adverse events	DN24-02	20	67
Total, serious adverse events	Standard of Care	17	72

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
DN24-02 vs Standard of Care: deaths from any cause	Trial comparisons
DN24-02 vs Standard of Care: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01353222

GET https://conductscience.org/api/trials/v1/NCT01353222/events?page=2

API reference For AI assistants